ERBB2 and breast carcinoma: The treatment of HER2 breast cancer is currently being explored through a phase 1b clinical trial, which incorporates an innovative combination of the BN-Brachyury vaccine, bifunctional antibody protein, class I histone deacetylase inhibitors, and targeted drugs.